AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 111 filers reported holding AKERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 8.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $593,051 | +11.6% | 11,725 | +3.0% | 0.00% | – |
Q2 2023 | $531,613 | +30.3% | 11,386 | +6.8% | 0.00% | – |
Q1 2023 | $407,851 | -20.4% | 10,660 | +14.0% | 0.00% | – |
Q4 2022 | $512,215 | +112.5% | 9,347 | +32.4% | 0.00% | – |
Q3 2022 | $241,000 | +7.6% | 7,060 | -8.4% | 0.00% | – |
Q1 2021 | $224,000 | – | 7,709 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
University of Wisconsin Foundation | 103,816 | $5,251,013 | 6.02% |
Boxer Capital, LLC | 1,676,733 | $84,809,155 | 4.52% |
Redmile Group, LLC | 1,769,684 | $89,510,617 | 4.26% |
Ghost Tree Capital, LLC | 250,000 | $12,645,000 | 4.16% |
Logos Global Management LP | 600,000 | $30,348,000 | 4.05% |
COMMODORE CAPITAL LP | 565,000 | $28,577,700 | 3.34% |
Yiheng Capital Management, L.P. | 1,221,674 | $61,792,271 | 3.15% |
SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,116,000 | 3.07% |
Atlas Venture Life Science Advisors, LLC | 359,251 | $18,170,915 | 2.81% |
Perceptive Advisors | 1,619,425 | $81,910,517 | 2.73% |